Overview

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive medication.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Pfizer